|
ERCC2 Asp312Asn and ERCC2 Lys751Gln polymorphisms and breast cancer risk |
|||||
| Genotype |
Cases (%) |
Controls (%) |
OR (95%CI) |
ORadj* (95%CI) |
P value |
|
|
|||||
| ERCC2 Asp312Asn |
|||||
| Asp/Asp |
403 (45) |
458 (46) |
1.00 (reference) |
1.00 (reference) |
|
| Asp/Asn |
383 (42) |
418 (42) |
1.04 (0.86–1.26) |
1.06 (0.93–1.21) |
|
| Asn/Asn |
118 (13) |
118 (12) |
1.14 (0.85–1.52) |
1.12 (0.86–1.46) |
0.68 |
| ERCC2 Lys751Gln |
|||||
| Lys/Lys |
121 (13) |
119 (11) |
1.00 (reference) |
1.00 |
|
| Lys/Gln |
419 (46) |
446 (44) |
0.92 (0.69–1.23) |
0.92 (0.80–1.05) |
|
| Gln/Gln |
368 (40) |
430 (43) |
0.84 (0.63–1.12) |
0.84 (0.64–1.09) |
0.43 |
|
* Adjusted for age | |||||
Bernard-Gallon et al. Molecular Cancer 2008 7:36 doi:10.1186/1476-4598-7-36 |
|||||